Compare · ACXP vs NVS
ACXP vs NVS
Side-by-side comparison of Acurx Pharmaceuticals Inc. (ACXP) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACXP and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $306.26B, about 52926.9x ACXP ($5.8M).
- ACXP has been more active in the news (6 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 1 for ACXP).
- Company
- Acurx Pharmaceuticals Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $5.8M
- $306.26B
- 1M return
- -
- +6.79%
- 1Y return
- -
- +22.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 5
- Recent ratings
- 1
- 25
Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ACXP
- New to The Street Show #780 Premieres Tonight on Bloomberg Television with Robo.ai, American Fusion, Stewards Investment Capital and FreeCast
- Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
- SEC Form 10-Q filed by Acurx Pharmaceuticals Inc.
- SEC Form 8-K filed by Acurx Pharmaceuticals Inc.
- Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
- Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
- SEC Form 8-K filed by Acurx Pharmaceuticals Inc.
- Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
- SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank